Targeted Therapies for Pancreatic Cancer

被引：63

作者：

Amanam, Idoroenyi ^{[1
]}

Chung, Vincent ^{[1
]}

机构：

[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA

来源：

CANCERS | 2018年 / 10卷 / 02期

关键词：

targeted therapy; personalized medicine; pancreas; PHASE-III TRIAL; GEMCITABINE PLUS PLACEBO; TUMOR-SUPPRESSOR GENE; HUMAN HOMOLOG; INHIBITION; SURVIVAL; ADENOCARCINOMA; MAINTENANCE; KRAS; MULTICENTER;

D O I：

10.3390/cancers10020036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic cancer is the third leading cause of cancer related death and by 2030, it will be second only to lung cancer. We have seen tremendous advances in therapies for lung cancer as well as other solid tumors using a molecular targeted approach but our progress in treating pancreatic cancer has been incremental with median overall survival remaining less than one year. There is an urgent need for improved therapies with better efficacy and less toxicity. Small molecule inhibitors, monoclonal antibodies and immune modulatory therapies have been used. Here we review the progress that we have made with these targeted therapies.

引用

页数：14

共 71 条

[1]

[Anonymous], NEWLINK GENETICS ANN

[2] A phase Ib/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts). [J].

Bekaii-Saab, Tanios S. ;

Starodub, Alexander ;

El-Rayes, Bassel F. ;

O'Neil, Bert H. ;

Shanda, Safi ;

Ciombor, Kristen Keon ;

Noonan, Anne M. ;

Hanna, Wahid Tewfik ;

Sehdev, Amikar ;

Shaib, Walid Labib ;

Mikhail, Sameh ;

Neki, Anterpreet S. ;

Oh, Cindy ;

Li, Youzhi ;

Li, Wei ;

Borodyansky, Laura ;

Li, Chiang .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[3]

Bockhorn M, 2003, CLIN CANCER RES, V9, P4221

[4] A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy [J].

Bodoky, Gyoergy ;

Timcheva, Constanta ;

Spigel, David Robert ;

La Stella, Phillip Joseph ;

Ciuleanu, Tudor Eliade ;

Pover, G. ;

Tebbutt, N. C. .

INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) :1216-1223

[5]

Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310

[6] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[7]

Bustinza-Linares E, 2010, FUTURE ONCOL, V6, P885, DOI [10.2217/fon.10.71, 10.2217/FON.10.71]

[8] Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer [J].

Catenacci, Daniel V. T. ;

Junttila, Melissa R. ;

Karrison, Theodore ;

Bahary, Nathan ;

Horiba, Margit N. ;

Nattam, Sreenivasa R. ;

Marsh, Robert ;

Wallace, James ;

Kozloff, Mark ;

Rajdev, Lakshmi ;

Cohen, Deirdre ;

Wade, James ;

Sleckman, Bethany ;

Lenz, Heinz-Josef ;

Stiff, Patrick ;

Kumar, Pankaj ;

Xu, Peng ;

Henderson, Les ;

Takebe, Naoko ;

Salgia, Ravi ;

Wang, Xi ;

Stadler, Walter M. ;

de Sauvage, Frederic J. ;

Kindler, Hedy L. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (36) :4284-+

[9] Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial [J].

Chantrill, Lorraine A. ;

Nagrial, Adnan M. ;

Watson, Clare ;

Johns, Amber L. ;

Martyn-Smith, Mona ;

Simpson, Skye ;

Mead, Scott ;

Jones, Marc D. ;

Samra, Jaswinder S. ;

Gill, Anthony J. ;

Watson, Nicole ;

Chin, Venessa T. ;

Humphris, Jeremy L. ;

Chou, Angela ;

Brown, Belinda ;

Morey, Adrienne ;

Pajic, Marina ;

Grimmond, Sean M. ;

Chang, David K. ;

Thomas, David ;

Sebastian, Lucille ;

Sjoquist, Katrin ;

Yip, Sonia ;

Pavlakis, Nick ;

Asghari, Ray ;

Harvey, Sandra ;

Grimison, Peter ;

Simes, John ;

Biankin, Andrew V. .

CLINICAL CANCER RESEARCH, 2015, 21 (09) :2029-2037

[10] Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513. [J].

Chiorean, E. Gabriela ;

McDonough, Shannon ;

Philip, Philip Agop ;

Swisher, Elizabeth M. ;

Pishvaian, Michael J. ;

Guthrie, Katherine ;

Lowy, Andrew M. ;

Hochster, Howard S. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 6 7 8 →